key: cord-0709519-erwgnkf1
authors: Trahtemberg, U.; Rottapel, R.; DosSantos, C.; Slutsky, A. S.; Baker, A. J.; Fritzler, M. J.
title: Anti-cardiolipin and other anti-phospholipid antibodies in critically ill COVID-19 positive and negative patients
date: 2021-02-23
journal: nan
DOI: 10.1101/2021.02.19.21252113
sha: 955cab8827ea57e919f7a5f363f9f51b450bf039
doc_id: 709519
cord_uid: erwgnkf1

Background: Reports of severe COVID-19 being associated with thrombosis, anti-phospholipid antibodies (APLA), anti-phospholipid syndrome (APS) have yielded disparate conclusions. Studies comparing COVID-19 patients with contemporaneous controls of similar severity are lacking. Methods: 22 COVID+ and 20 COVID- patients with respiratory failure admitted to intensive care were studied longitudinally. Demographic and clinical data were obtained from the day of admission. APLA testing included anti-cardiolipin (aCL), anti-{beta}2glycoprotein 1 ({beta}2GP1), anti-domain 1 {beta}2 glycoprotein 1 ({beta}2GP1) and anti-phosphatidyl serine/prothrombin complex (PS/PT). Anti-nuclear antibodies (ANA) were detected by immunofluorescence and antibodies to cytokines by a commercially available multiplexed array. ANOVA was used for continuous variables and Fisher exact test was used for categorical variables with =0.05 and the false discovery rate at q=0.05. Results: APLA were predominantly IgG aCL (48%) followed by IgM (21%) in all patients, with a tendency toward higher frequency among the COVID+. aCL was not associated with surrogate markers of thrombosis but IgG aCL was strongly associated with worse disease severity and higher ANA titers regardless of COVID-19 status. An association between aCL and anti-cytokine autoantibodies tended to be higher among the COVID+ cohort. Conclusions: Positive APLA serology was associated with more severe disease regardless of COVID-19 status.

Anti-phospholipid antibodies (APLA) are biomarkers of a spectrum of clinical features observed 58 in anti-phospholipid syndrome (APS) 1 

involving multiple organs and having various presentations 1 . APLA that are components of APS 60 criteria include IgG and/or IgM anti-cardiolipin (aCL), -β2-glycoprotein1 (GP1), and the "lupus 61 anticoagulant" (LAC) 2 . Other non-criteria APLA such as anti-phosphatidylserine/prothrombin 62 (PS/PT) complex, -PT, and -domain 1 of β2-GP1 have also found a diagnostic niche in APS 3 4 . 63

One of the salient features of COVID-19 is the development of thrombotic events associated 65 with severe morbidity and mortality 5-8 . In the context of systemic inflammation and 66 dysregulated immunity 9 , some reports have linked APLA to these thromboses 10 This is an observational cohort study of patients admitted to St. Michael's Hospital (Toronto,  77 ON, Canada), as approved by the Research Ethics Board (REB# 20-078). Informed consent was 78 obtained from all patients or their legal surrogates. Inclusion criteria were age ≥18 years, 79 admission to intensive care unit (ICU) with acute respiratory failure. Exclusion criteria were 80 inability to ascertain the primary outcome or obtain a baseline blood sample, and SARS-CoV2 81 infection in the 4 weeks prior to admission. COVID-19 status was determined with PCR of 82 nasopharyngeal swabs and/or endotracheal aspirates. Follow-up was 3 months post-ICU 83 admission or hospital discharge. Primary outcome was death in the ICU. Secondary outcomes 84 were in hospital-death, ICU utilization metrics, organ dysfunction measures and severity scores. 85

Clinical data and serum samples were collected longitudinally at days 0, 1, 3, 5, 7 and 10; after 86 day 10 or ICU discharge. Anti-CL, anti-β2-GP1 and anti-PS/PT were tested for IgG and IgM, as 87 well as IgG anti-domain 1 β2-GP1; all by ELISA or chemiluminescence (Inova Diagnostics, San 88 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Table 1) ; interestingly, fewer patients had elevated titers of IgM aCL (n=9, 108 21%), with only 2 patients having IgM without IgG. Although more COVID + had aCL antibodies, 109 the difference was not statistically significant. Longitudinally testing for anti-β2-GP1 and anti-110 PS/PT for IgG and IgM, as well as domain 1 β2-GP1 IgG revealed only one patient (COVID + ) with 111 positive serology for any of these autoantibodies. This patient seroconverted to IgM anti-PS/PT 112 at days 5-7 of ICU hospitalization. Table 2 shows the temporal development of the aCL IgG and 113 IgM antibodies stratified by COVID status. Late appearing (beyond 10 days after admission) aCL 114 antibodies were not included in the statistical analyses to avoid survival and availability bias. 115

Anti-CL were not associated with age or sex (not shown). 116 117 aCL vs disease severity, platelet counts and need for anticoagulation. Patients positive for aCL 118 not reach statistical significance after adjusting for multiple comparisons (Table 3) . These trends 120 remained when analyzed separately for COVID + and COVID -(not shown). Anti-CL IgG positive 121 patients showed no significant differences in platelet counts, platelet to neutrophil ratio or the 122 need for therapeutic anticoagulation (Table 3) . 123 124 aCL association with ANA, antigen-specific autoantibodies and anti-cytokine autoantibodies. 125

Although aCL IgG positivity was not associated with the presence of HEp-2 IFA ANA at a dilution 126 of 1:160, it was significantly associated with higher ANA titers (p= 0.02), and this trend remained 127 when analyzing the COVID + and COVIDpatients separately. IgG aCL positivity was also 128 significantly associated with anti-cytokine autoantibodies, both when analyzed for positive or 129 high-positive anti-cytokine titers (p=0.003 for both, adjusted for multiple comparisons); this was 130 not related to any particular anti-cytokine autoantibody, although anti-interferon-γ, anti-IL10 131 and anti-IL-17f were the most prevalent (supplemental table 2). When analyzing the aCL IgG 132 positive according to their COVID-19 status, the COVID + had significantly higher levels of anti-133 cytokine autoantibodies than the COVID -(supplemental Table 3 ). Anti-CL IgG was not associated 134 with antigen-specific autoantibodies, including SLE and myositis-related autoantibodies (not 135 shown). 136

The key observation of this study is that patients with positive IgG aCL showed a trend toward 139 more severe disease regardless of whether they were COVID + and COVID -. That is, while COVID + 140 patients showed non-significant trends towards worse respiratory outcomes when compared to 141 COVID -, aCL status had an independent association with disease severity, and did not modulate 142 the outcomes differentially based on COVID status. The pathological significance of aCL 143 seropositivity is unclear since there were no major differences in platelet counts or thrombotic 144 events in the two cohorts. Others have reported a high prevalence of aCL autoantibodies among 145 COVID + patients, but these studies lacked contemporaneous COVIDcontrol groups of similar 146 disease severity 5 6 16 17 . 147

Although aCL tended to associate with COVID + , they did not associate with the presence of other 149 antigen-specific autoantibodies, although they had a strong association with certain anti-150 cytokine autoantibodies. Interestingly, some patients had positive IgG aCL serology on ICU 151 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (supplementary table 1 ). These observations suggest that aCL positivity in the setting of acute 153 severe respiratory illness may be a marker of a unique phenotype with variable temporal 154 expression of aCL and anti-cytokine antibodies. The temporal dynamic is evidenced by the 155 relatively long timeframe from symptom onset to ICU admission to the development of IgG aCL 156 (Table 3) The main limitation of our study is the small sample size. The strengths of our study include its 178 prospective, contemporaneous COVIDcohort with similar severity of disease. Importantly, we 179 tested a broad APLA serological panel longitudinally, providing a more robust assessment of its 180 true prevalence and incidence than in other reported studies; this is particularly relevant for 181 such acutely ill patients with dynamic clinical courses. Finally, our use of an extensive serological 182 panel allowed us to better characterize the broad phenotype associated with aCL. 183 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

What is already known about this subject? 185

• COVID-19 is associated with coagulopathy and high morbidity and mortality. 186

• COVID-19 shares some of these clinical features with anti-phospholipid syndrome. 187 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

• Patients and public were not involved in the design of the study. During the initial phases of 235 the study, we obtained feedback from the patients and their substitute decision makers. 236

Their concerns, questions and preferences were incorporated into improved processes for 237 consent and collection of biological samples. The consent forms have checkboxes with 238 optional aspects of the study, to accommodate different patient preferences. The results of 239 the study will be disseminated in lay versions by St. Michael's Hospital public relations and 240 communications departments for the benefit of the public. 241 242 243 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 23, 2021. ; https://doi.org/10.1101/2021.02.19.21252113 doi: medRxiv preprint

A Covid-19 Patient 281 with Complement-Mediated Coagulopathy and Severe Thrombosis

Anti-cardiolipin IgG 284 autoantibodies are an independent risk factor of COVID-19 severity

Role of Infectious Diseases in the 287

Including Its Catastrophic Variant)

Coagulopathy of COVID-19 and antiphospholipid 290 antibodies

Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome

Lupus anticoagulant is frequent in patients with Covid-19

Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid 297

Lupus Anticoagulant in Patients with Covid-19

A Reality Check on Antiphospholipid 301 Antibodies in COVID-19-Associated Coagulopathy

Antiphospholipid antibodies and thrombosis 304 in patients with COVID-19

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity